BIVN 401

Drug Profile

BIVN 401

Alternative Names: BIVN-401; Methylene blue - Oklahoma Medical Research; Methylthioninium chloride - Oklahoma Medical Research; Suvus; Virostat

Latest Information Update: 15 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Oklahoma Medical Research Foundation
  • Developer Bioenvision
  • Class Antivirals; Phenothiazines; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis C
  • Discontinued Influenza virus infections; West Nile virus infections

Most Recent Events

  • 05 Dec 2008 No development reported - Preregistration for Hepatitis C in Egypt (PO)
  • 23 Oct 2007 Bioenvision has been acquired by Genzyme Corporation
  • 12 Sep 2007 Discontinued - Phase-II for Hepatitis C treatment in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top